The disease is named after Alois Alzheimer, who described distinctive brain changes in 1906 after caring for a woman with difficulties involving memory, language and behaviour. The deposits now called amyloid plaques and tau tangles became central to its study.
Later research showed that similar processes could affect older adults, not only unusually young patients. For many years, care focused mainly on symptom management and support. More recent research has added biological tests and disease-targeted medicines for selected early-stage patients.
This is progress, but it does not mean that a positive test predicts an exact course or that treatment restores lost abilities. Clinical care still depends on function, safety, preferences and support.